Blood | 2023
A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.
Magenau J, Jaglowski S, Uberti J, Farag SS, Riwes MM, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang MJ, Burns LJ, Liu Y, Zheng P, Reddy P
PubMed
PMID: 37647633
Abstract
Related Articles
CIBMTR Study #: CS20-04